SymBio Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Solasia Pharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Chiome Bioscience 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

SanBio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07692178, evaluating EX-03 in Varicose Ulcer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into JPRN-jRCT2021260024, evaluating HRS-5346 in Unmet-Need Clinical Development: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07691645, evaluating Immunotherapy in Blood Stasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07693543, evaluating Matched Placebo (Capsules) in Chronic Kidney Diseases: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07694089, evaluating Azeliragon in Edema: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07692672, evaluating Granulocyte Colony-Stimulating Factor(G-CSF) in Infertility, Female: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07694297, evaluating NTZ 500mg BID on top of SOC in Decompensated cirrhosis of liver: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into CTR20262661, evaluating Tislelizumab in Esophageal Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.